Investment Rating - The report maintains an "Outperform" rating for Genscript Biotech [2][4][6] Core Insights - The deconsolidation of Legend Biotech has led to a significant profit improvement for Genscript, with a profit from discontinued operations of approximately $3 billion, compared to a loss of about $518 million in the same period in 2023 [7][17] - The company expects a positive trend for its continuing business segments in 2025, with projected revenues of $938 million, representing a year-on-year growth of 58% [2][8] - The total equity valuation of Genscript is estimated at $6.296 billion, translating to a target price of HK$22.78 per share [6][17] Summary by Segment Life Sciences Segment - Expected revenue for 2025 is $523 million, with a year-on-year growth rate of 15% and an adjusted operating profit of $104 million [13][14] - The segment's revenue in 2024 was approximately $454.9 million, up by 10.2% year-on-year, with an adjusted gross profit of about $237.7 million [14][17] Biologics Development Services Segment - Projected Fee-for-Service revenue for 2025 is $113 million, up by 19% year-on-year [14][15] - The segment's revenue in 2024 was about $95 million, down by 13.2% year-on-year, but showed signs of recovery in the second half of 2024 [14][17] Industrial Synthetic Biology Products Segment - Expected revenue for 2025 is $67 million, with a year-on-year growth rate of 25% [15][16] - The segment's revenue in 2024 was approximately $53.7 million, up by 24.6% year-on-year [14][17] Legend Biotech - After the deconsolidation, the market capitalization of Legend Biotech was $6.8 billion, with Genscript holding a 47.51% stake valued at approximately $3.231 billion [16][17]

Investment Rating - The report maintains an "Outperform" rating for Genscript Biotech [2][4][6] Core Insights - The deconsolidation of Legend Biotech has led to a significant profit improvement for Genscript, with a profit from discontinued operations of approximately $3 billion, compared to a loss of about $518 million in the same period last year [7][17] - The continuing business segments are expected to show positive trends in 2025, with revenue from continuing operations projected at approximately $594.5 million, representing a year-on-year increase of 6.1% [3][14] - The total equity valuation of Genscript is estimated at $6.296 billion, translating to a target price of HK$22.78 per share [6][17] Summary by Segment Life Sciences Segment - Expected revenue for 2025 is $523 million, with a year-on-year growth rate of 15% and an adjusted operating profit of $104 million, also growing by 15% [13][14] - The segment's revenue in 2024 was approximately $454.9 million, up by 10.2% year-on-year, with an adjusted gross profit of about $237.7 million [3][14] Biologics Development Services Segment - Projected Fee-for-Service revenue for 2025 is $113 million, up by 19% year-on-year [14] - The segment's revenue in 2024 was about $95 million, down by 13.2% year-on-year, but showed a recovery with a growth rate of about 38% in the second half of 2024 [3][14] Industrial Synthetic Biology Products Segment - Expected revenue for 2025 is $67 million, with a year-on-year growth rate of 25% [14] - The segment's revenue in 2024 was approximately $53.7 million, up by 24.6% year-on-year, with an adjusted gross profit of about $22.6 million [3][14] Legend Biotech - Following the deconsolidation, the market capitalization of Legend Biotech was approximately $6.8 billion, with Genscript holding a 47.51% stake valued at about $3.231 billion [5][16]

Financial Data and Key Metrics Changes - The group's revenue increased by 6.1% year over year to approximately $590 million [38] - The net profit recorded was around $2.9 billion, primarily due to a one-time investment gain from the deconsolidation of Legend [38] - Adjusted net profit from continuing operations remained stable at approximately $59.8 million [38] - The Life Science Group's revenue was approximately $455 million, representing a 10.2% year-over-year growth [38] - Adjusted operating profit for the Life Science Group was about $90.4 million, reflecting a 15.5% increase year over year [39] Business Line Data and Key Metrics Changes - The Protein segment, representing about 25% of Life Sciences revenue, achieved nearly 50% revenue growth in 2024 [6][22] - ProBio's revenue was $95 million, experiencing a decline of about 13.2% year over year [39] - Bestime's revenue grew by about 24.6% to $53.7 million, achieving an adjusted operating profit of approximately $2.1 million [39][44] Market Data and Key Metrics Changes - Revenue from industrial customers increased largely due to the development of more multinational companies [40] - Revenue from China accounted for about 19% of Bestime's revenue, indicating a strong market presence [34] - The addressable market for protein regions is over $4.5 billion, with growing demand driven by antibody drug discovery and AI-driven protein engineering [22] Company Strategy and Development Direction - The company aims for full-year revenue growth for the Life Science business to be around 10% to 15% in 2025 [49] - ProBio is targeting a revenue growth of 15% to 20% for 2025, excluding the impact of the Lenovo deal [49] - Bestime is targeting constant currency revenue growth of 20% to 25% with a gross margin around 45% [49] Management's Comments on Operating Environment and Future Outlook - Management noted a strong recovery in the second half of 2024, driven by robust demand from AI-related applications and antibody drug research [40] - The company is confident in maintaining growth trends due to continuous R&D investment and expansion into overseas markets [56] - Management expressed optimism about improving profitability in the coming years despite short-term margin pressures [64] Other Important Information - The company has over 250 patents and more than 480 patents in the application process, positioning it as a global leader in the industry [11] - The company joined the United Nations Global Compact, solidifying its commitment to sustainability [12] - A new facility for Bestime is under construction, representing a total investment of RMB 800 million, slated for completion by 2027 [37] Q&A Session Summary Question: Order trend and outlook for 2025 - Management expects faster growth in Europe and the U.S., with moderate growth in China and Asia Pacific [54] Question: Net margin outlook for Life Science segments - Life Science business is targeting growth of 10% to 15% with flat gross margin [55] Question: Impact of global tariffs - Management believes tariffs will not significantly impact business results, focusing on quality and delivery speed [62][63] Question: Gross profit margin for Life Science Group - Short-term profit margins may decrease due to local production expansion, but long-term profitability is expected to improve [64] Question: CapEx guidance for 2025 - Overall CapEx spending will be roughly flat compared to 2024, with increases in specific segments like Bestime [76]

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The prospects for biomanufacturing are broad, contributing to industrial upgrades. Biomanufacturing, centered on industrial biotechnology, utilizes enzymes and microbial cells in the processing of target products, including bio-based materials, chemicals, and bioenergy. Synthetic biology plays a crucial role as a platform technology in biomanufacturing. The global synthetic biology market is expected to maintain rapid growth, reaching nearly $50 billion by 2028 [3][4][22]. - Technological breakthroughs combined with policy support are driving the synthetic biology industry forward. Factors such as reduced costs of gene synthesis and sequencing, along with advancements in efficient gene editing technologies, provide a solid technical foundation for the rapid development of synthetic biology. Governments worldwide are increasingly prioritizing the development of synthetic biology, with various supportive policies being introduced [4][28]. - Synthetic biology is reshaping industrial models, offering more efficient and environmentally friendly synthesis solutions. It addresses issues associated with traditional chemical synthesis and natural extraction methods, such as high costs, limited yields, and environmental pollution. With breakthroughs in gene editing, enzyme engineering, and metabolic engineering, synthetic biology not only reduces drug production costs but also enhances capacity, enabling large-scale industrial production [4][5]. Summary by Sections Industry Overview - Biomanufacturing is defined as the processing of target products using industrial biotechnology, involving enzymes and microbial cells. Synthetic biology is a key platform technology in this field, enabling the design and construction of biological systems for various applications [13][14]. Policy Support and Technological Breakthroughs - The development of synthetic biology is supported by various policies and technological advancements. Governments are investing in funding, technology, and talent development to foster innovation and industrialization in this field [28][29]. - Major countries are establishing synthetic biology research centers and networks, with the UK and the US leading in policy initiatives to promote synthetic biology [29][30]. Synthetic Biology's Impact on Industrial Models - Synthetic biology is transforming production methods, achieving tasks that traditional biotechnologies cannot, while providing more efficient and eco-friendly synthesis options. This shift is crucial for addressing environmental challenges and enhancing production efficiency [4][5]. Investment Recommendations - Companies to watch include Chuan Ning Biological, Kingfisher Biotech, Kylin Biotech, and Huaxi Biological, which are positioned to benefit from the growth in synthetic biology [5].

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The bio-manufacturing sector has vast potential and is poised to drive a new wave of industrial revolution, leveraging industrial biotechnology to produce bio-based materials, chemicals, and bioenergy [3][4] - The global synthetic biology market is expected to maintain rapid growth, projected to approach $50 billion by 2028, with a compound annual growth rate (CAGR) of approximately 24% from 2023 to 2028 [22][24] - Technological breakthroughs and policy support are driving the synthetic biology industry forward, with significant advancements in gene synthesis, sequencing, and editing technologies [4][37] Summary by Sections Industry Overview - Bio-manufacturing utilizes industrial biotechnology, enzymes, and microbial cells, playing a crucial role in producing bio-based materials and chemicals [13] - Synthetic biology is a design-driven science that re-engineers biological systems for useful purposes, with applications across various sectors including healthcare, agriculture, and chemicals [13][22] Policy Support and Technological Breakthroughs - Governments worldwide are increasingly prioritizing synthetic biology, with strategic plans and funding initiatives to support its development [28][29] - The reduction in costs for gene synthesis and sequencing technologies has laid a solid foundation for the rapid advancement of synthetic biology [37] Synthetic Biology Reshaping Industry Models - Synthetic biology is transforming production models, offering more efficient and environmentally friendly synthesis solutions compared to traditional methods [4][22] - The industry is expected to significantly reduce carbon emissions, with estimates suggesting a reduction of 1 to 2.5 billion tons of CO2 annually by 2030 through industrial biotechnology [4] Related Companies - Companies to watch include Chuan Ning Bio, Kingfisher Biotech, and Kailai Ying, which are positioned to benefit from advancements in synthetic biology [5] Investment Recommendations - The report suggests focusing on companies like Chuan Ning Bio, Kingfisher Biotech, and others that are leveraging synthetic biology for growth [5]

Fundraising - A total of 81 new funds were registered this week, with a total scale of 53.504 billion RMB, the largest being the Beijing Economic and Technological Development Zone Government Investment Guidance Fund Phase II, which raised 10.00 billion RMB [3] - As of this week, the cumulative number of registered private equity funds is 631, with a total scale of 555.875 billion RMB [3] Investment - There were 57 investment events this week, with disclosed investment amounts totaling 3.886 billion RMB, the largest being an investment of over 500 million RMB in Shenzhen Ruidelin Biotechnology Co., Ltd. by Shenzhen Songhe Capital Management Co., Ltd. and others [5][6] - Shenzhen Ruidelin Biotechnology Co., Ltd. focuses on synthetic biology technology and aims to create innovative products and solutions in the field of synthetic biology [5] Mergers and Acquisitions - A total of 24 M&A events occurred this week, with disclosed transaction amounts reaching 11.803 billion RMB, the largest being an investment of 2.6 billion RMB by Fengxin New Era New Energy Materials Co., Ltd. and Jiangxi Feiyu New Energy Technology Co., Ltd. in Yichun Shengyuan Lithium Industry Co., Ltd. [12][13] - Yichun Shengyuan Lithium Industry Co., Ltd. is a mineral exploration and mining service provider, and the investment aims to enhance its business development [12] IPOs - Three companies went public this week, raising a total of 1.43 billion RMB, with the largest being Microbus International, which raised 80 million USD through an IPO on NASDAQ [16][17] - Microbus International provides a real-time bus operation information query platform, enhancing user convenience in ticket purchasing and verification [16]

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The report highlights the ongoing active research in life sciences and the global wave of biotechnology revolution, which is accelerating integration into economic and social development, providing new solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [3][4]. Summary by Sections 1.1 Secondary Market Performance - The synthetic biology sector saw an overall increase of 6.17% in stock performance during the week of February 24 to February 28, 2025, ranking first among sectors [14]. 1.2 Company Business Progress - Domestic companies are making significant advancements, such as: - Zhongyuan Biological's 350,000 tons/year green methanol project is progressing with the first phase expected to be completed in 24 months [22]. - Longi Green Energy and China Energy Construction Group signed a project for 300,000 tons/year green methanol, with a total investment of 6 billion yuan [22]. - Henghui Security's biodegradable polyester rubber project is on track to start production in Q4 2025 [23]. 1.3 Industry Financing Tracking - Financing activities in the synthetic biology sector are accelerating, with nearly a hundred companies completing new rounds of financing at the beginning of 2025. Notable examples include: - Nanjing Senqi New Materials Technology completed a multi-million yuan financing round, focusing on bio-based nanocellulose [28]. - Vivici, a precision fermentation dairy product company, raised €32.5 million in Series A funding to launch a new product [28]. 1.4 Company R&D Directions - Domestic research institutions are achieving breakthroughs in bio-based materials, such as: - The Ningbo Institute of Materials Technology and Engineering has made progress in synthesizing bio-based long-chain polyols [31]. - Wanhua Chemical launched a bio-based 1,3-butanediol product aimed at the cosmetics industry, emphasizing sustainability and low carbon emissions [31].

本周募资情况 本周新登记股权投资基金管理人共计0家，取消备案登记3家，全年截至目前累计股权投 资基金管理人数量为11家。本周新增备案基金数量为 81只 ，规模总计 535.04亿元 ，本周备案基金募资最多的为北京经济技术开发区政府投资引导基金二期（有限合 伙），募集100.00亿人民币。全年截至目前累计股权投资备案基金数量为631只，规模 总计5558.75亿元。（2025年2月21日-2025年2月27日） 新备案基金地域分布TOP5 涉及总金额693.36亿元人民币。 作者 | 私募通 来源 | 决策投资圈 （ID：PEDATAMAX） 清科创业（01945.HK）旗下私募通统计：截至本周五下午，募资、投资、上市和并购 共 165起 事件，涉及总金额 693.36亿 人民币。从交易金额来看，本周金额较大事件 是：2025年2月25日，奉新时代新能源材料有限公司、江西飞宇新能源科技有限公司对 宜春盛源锂业有限责任公司进行增资，出资金额是26.00亿人民币。从交易事件地域分 布看，目前主要分布在广东省、江苏省和北京市，占比为广东省19.1%，江苏省 14.3%，北京市13.1%。 01 02 本周投资情况 清 ...

Investment Rating - The report maintains an "A" rating for the new materials industry, indicating a positive outlook for the sector [1]. Core Insights - The chemical raw materials sector is currently experiencing a bottoming phase, with a slowdown in capacity expansion and a potential alleviation of intense competition and price wars. The overall profit margin for the industry is expected to remain between 3% and 5% in 2024, which is at a historical low. However, with the central economic work conference emphasizing the need to address "involution" competition, there is potential for improved industry order and profit recovery [1][34]. Summary by Sections 1. Market Performance and Valuation - The new materials index has shown significant volatility, underperforming the Shanghai Composite Index by 10.6% as of December 27, 2024. The index's performance was particularly weak in the first three quarters of 2024 but saw a recovery in the fourth quarter due to favorable policies [15][20]. 2. Focus Areas 2.1 Supply and Demand Dynamics - The vitamin sector is expected to maintain high prices for Vitamin E due to limited supply recovery from BASF's production facilities, which are aging and unable to meet demand. The report suggests monitoring companies like New Hope Liuhe and Zhejiang Medicine [42][59]. - The renewable energy materials sector is projected to benefit from a stable increase in wind power demand, with a significant rise in installed capacity and a self-regulatory agreement among wind turbine manufacturers to mitigate price competition. Companies like Times New Material and Mega Chip Color are highlighted for investment [44][60]. 2.2 Emerging Industry Opportunities - The bio-manufacturing sector is positioned for growth, particularly in synthetic biology and sustainable aviation fuel (SAF). The report emphasizes the importance of product selection and platform capabilities for companies in this space, recommending firms like Huaheng Biological and Meihua Biological [48][50]. - The special coatings market is expected to grow due to increasing military expenditures and the need for stealth materials. Companies such as Huaqin Technology and Jiachih Technology are noted for their potential in this area [52][61]. - The semiconductor materials sector is anticipated to benefit from the recovery of consumer electronics and AI applications, with a focus on domestic production capabilities. Companies like Stik and Aisen are recommended for investment [56][61]. - The humanoid robotics market is projected to drive demand for PEEK materials, with domestic companies expected to gain market share due to cost advantages. The report suggests monitoring firms like Zhongxin Fluorine Materials and Zhongyan Co. [58][61].

华康股份 2024 年度董事会工作报告 浙江华康药业股份有限公司 2024 年度董事会工作报告 2024 年，公司董事会严格按照《公司法》《公司章程》《上市公司治理准则》 《上海证券交易所股票上市规则》等法律法规以及公司制度的规定，恪尽职守， 切实履行股东大会赋予的各项职责，严格执行股东大会各项决议，勤勉尽责开展 各项工作；积极推进董事会各项决议实施，不断规范公司法人治理结构，保证董 事会科学决策和规范运作。现将公司董事会 2024 年度工作情况汇报如下： 一、2024 年度经营讨论分析 公司以"做世界领先的糖醇专家"为企业愿景，坚持执行"深耕主业、规模 倍增、卓越运营、管理变革"的战略目标和规划，持续筑牢主营业务根基，提升 核心竞争力，稳健发展主营业务。同时积极探索并开拓新产品领域，开拓新的增 长空间，为企业的长远发展注入源源不断的活力。 "200 万吨玉米精深加工健康食品配料项目"分两期建设，其中一期项目 1 华康股份 2024 年度董事会工作报告 "100 万吨玉米精深加工健康食品配料项目"于 2022 年 8 月启动，一期项目建 设期为 5 年，分两个阶段，第一阶段建设期 2 年，主要以液体糖浆类及部 ...